| Budget Amount *help |
¥23,530,000 (Direct Cost: ¥18,100,000、Indirect Cost: ¥5,430,000)
Fiscal Year 2017: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2016: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2015: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2014: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Outline of Final Research Achievements |
We have originally developed a novel technique to induce microglia-like (iMG) cells directly from human peripheral blood (monocytes) by applying only two cytokines IL-34 and GM-CSF within two weeks without any gene modifications. Compared to the iPS cells, our iMG technique is simpler and has advantages of time and cost management. We have revealed abnormalities in cellular responses of iMG cells derived from patients with (1) Nasu-Hakola disease which is a known primary microglia disease. (2) bipolar disorder, and (3) fibromyalgia.
Direct conversion technique to produce induced-neuronal (iN) cells from human fibroblasts within 2 weeks is expected to discover unknown neuronal phenotypes of neuropsychiatric disorders. We have developed early-stage iN cells within a week. We have revealed unique gene expression profiles in iN cells and early-stage iN cells from patients with neurofibromatosis type 1 (NF1).
|
